CONTE, PIERFRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 43.191
AS - Asia 23.154
EU - Europa 10.493
AF - Africa 4.683
SA - Sud America 3.785
OC - Oceania 466
Continente sconosciuto - Info sul continente non disponibili 218
Totale 85.990
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 40.703
SG - Singapore 6.829
VN - Vietnam 3.454
CN - Cina 3.420
HK - Hong Kong 2.595
BR - Brasile 2.049
IT - Italia 1.248
FI - Finlandia 1.185
FR - Francia 1.121
IN - India 819
SE - Svezia 767
DE - Germania 758
BD - Bangladesh 563
PL - Polonia 550
RU - Federazione Russa 466
IQ - Iraq 433
GB - Regno Unito 426
TR - Turchia 383
AR - Argentina 323
JP - Giappone 292
NL - Olanda 287
PH - Filippine 277
PK - Pakistan 277
ID - Indonesia 257
SA - Arabia Saudita 248
CO - Colombia 214
UA - Ucraina 213
EC - Ecuador 205
MX - Messico 201
ZA - Sudafrica 193
KR - Corea 187
CA - Canada 185
UZ - Uzbekistan 185
AT - Austria 181
TN - Tunisia 181
VE - Venezuela 173
ES - Italia 171
IE - Irlanda 169
AO - Angola 168
JO - Giordania 167
PS - Palestinian Territory 165
MA - Marocco 162
RS - Serbia 161
IL - Israele 157
CL - Cile 156
MY - Malesia 153
PE - Perù 153
KE - Kenya 148
ET - Etiopia 146
AE - Emirati Arabi Uniti 143
TH - Thailandia 143
BJ - Benin 141
GR - Grecia 141
DZ - Algeria 140
AZ - Azerbaigian 138
PY - Paraguay 137
CH - Svizzera 136
HU - Ungheria 136
PA - Panama 136
AL - Albania 135
CR - Costa Rica 135
JM - Giamaica 135
LB - Libano 135
EG - Egitto 134
UY - Uruguay 133
CI - Costa d'Avorio 130
MR - Mauritania 130
LV - Lettonia 129
CZ - Repubblica Ceca 127
DO - Repubblica Dominicana 127
MD - Moldavia 127
BE - Belgio 126
BB - Barbados 125
CG - Congo 125
HN - Honduras 125
NP - Nepal 125
BA - Bosnia-Erzegovina 124
MK - Macedonia 122
PT - Portogallo 122
KG - Kirghizistan 121
ML - Mali 120
YT - Mayotte 120
GE - Georgia 119
GF - Guiana Francese 119
LA - Repubblica Popolare Democratica del Laos 119
LC - Santa Lucia 119
BO - Bolivia 117
BZ - Belize 117
CM - Camerun 117
PR - Porto Rico 117
CU - Cuba 116
GT - Guatemala 116
NI - Nicaragua 115
EE - Estonia 114
SK - Slovacchia (Repubblica Slovacca) 114
CW - ???statistics.table.value.countryCode.CW??? 113
BY - Bielorussia 112
LY - Libia 112
NO - Norvegia 112
YE - Yemen 112
Totale 80.327
Salva come PNG Salva come JPEG
Città #
Fairfield 5.857
Ashburn 4.119
Woodbridge 3.997
Singapore 3.856
Houston 3.253
San Jose 2.800
Ann Arbor 2.752
Hong Kong 2.373
Cambridge 2.034
Seattle 2.033
Wilmington 1.901
Chandler 1.852
Boardman 1.052
Ho Chi Minh City 983
Hanoi 693
Helsinki 606
San Diego 591
Princeton 579
Medford 576
Lauterbourg 507
Los Angeles 477
Beijing 469
Dong Ket 468
Des Moines 467
Bytom 392
Santa Clara 366
Nanjing 349
Munich 305
New York 267
Padova 247
Chicago 204
São Paulo 185
Baghdad 178
Da Nang 173
Tokyo 172
Roxbury 166
Tashkent 156
Guangzhou 155
Amman 150
Hefei 146
Luanda 138
Cotonou 133
Dublin 132
Addis Ababa 130
Council Bluffs 127
Baku 126
Panama City 126
Abidjan 122
Nouakchott 122
Haiphong 118
Buffalo 117
Nairobi 115
London 114
Bridgetown 113
Castries 111
Shenyang 110
Bamako 109
Managua 108
Riga 107
San José 107
Nassau 106
Jeddah 105
Dakar 104
Havana 103
Libreville 103
Montevideo 103
Vienna 103
Ulan Bator 102
Vientiane 102
Amsterdam 101
Hebei 100
Phnom Penh 100
Lusaka 99
Bishkek 97
Antananarivo 95
Noumea 94
Dushanbe 93
Kampala 93
Conakry 92
Milan 92
Lahore 91
Lima 90
Nanchang 90
Podgorica 90
Cayenne 89
Frankfurt am Main 88
Accra 87
Praia 86
Tbilisi 86
Willemstad 86
Harare 85
Kinshasa 85
Istanbul 84
Jiaxing 84
Maputo 84
Dallas 83
Belgrade 82
Tallinn 80
Andorra la Vella 79
Gaborone 79
Totale 53.986
Salva come PNG Salva come JPEG
Nome #
0.1 grams of sub-cutaneous adipose tissue (SCAT) as source of adult multipotent mesenchymal stromal cells (MSC) for cell-based therapies. 521
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 421
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 367
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 359
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation 356
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 353
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 350
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 329
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 317
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 308
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 305
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model 305
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 288
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 286
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 283
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 282
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 282
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 281
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 280
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 277
Ribociclib as first-line therapy for HR-positive, advanced breast cancer 276
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 275
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 275
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 275
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 273
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 273
LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab 272
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 271
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 270
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 268
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 268
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 265
Immune characterization of breast cancer metastases: Prognostic implications 264
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 263
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 262
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman 261
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 259
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 259
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 259
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 257
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature 255
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 255
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 251
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 251
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study 249
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 248
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 245
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 243
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 243
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 243
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 242
Evolution of HER2-low expression from primary to recurrent breast cancer 242
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 238
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 238
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer 237
Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy 232
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 229
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 228
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer 227
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 224
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 224
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 224
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors 223
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 223
Olaparib for the treatment of breast cancer 219
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 219
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 217
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 216
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 216
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment 216
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 215
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 213
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 211
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 210
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer 210
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 209
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 208
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 208
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 206
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 205
Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer 204
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer 202
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 202
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 201
Achievements and unmet needs in the management of advanced ovarian cancer 200
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 199
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 199
Labelled micelles for the delivery of cytotoxic Cu(II) and Ru(III) compounds in the treatment of aggressive orphan cancers: design and biological in vitro data 197
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 196
GD2 expression in breast cancer 196
Effects of sulfonylureas on tumor growth: A review of the literature 196
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 195
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 194
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE 194
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 194
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 193
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 193
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients 193
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 193
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 193
Totale 24.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 240.856
article - articoli 234.082
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 842
patent - brevetti 761
selected - selezionate 0
volume - volumi 3.453
Totale 479.994
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.395 0 0 0 0 0 0 0 0 0 0 572 823
2021/20227.498 257 976 991 545 436 388 523 715 322 223 622 1.500
2022/20234.395 1.028 290 114 482 795 483 24 273 573 56 204 73
2023/20242.112 142 277 220 142 138 241 120 102 75 69 298 288
2024/20259.467 40 677 532 268 1.313 234 460 845 943 319 1.422 2.414
2025/202640.450 997 3.984 6.450 8.067 2.920 1.705 4.772 3.078 4.686 2.390 1.401 0
Totale 86.394